全文获取类型
收费全文 | 2711篇 |
免费 | 179篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 102篇 |
儿科学 | 143篇 |
妇产科学 | 102篇 |
基础医学 | 356篇 |
口腔科学 | 47篇 |
临床医学 | 308篇 |
内科学 | 412篇 |
皮肤病学 | 69篇 |
神经病学 | 210篇 |
特种医学 | 217篇 |
外科学 | 363篇 |
综合类 | 110篇 |
一般理论 | 4篇 |
预防医学 | 190篇 |
眼科学 | 14篇 |
药学 | 186篇 |
中国医学 | 1篇 |
肿瘤学 | 79篇 |
出版年
2022年 | 15篇 |
2021年 | 36篇 |
2020年 | 24篇 |
2019年 | 34篇 |
2018年 | 46篇 |
2017年 | 33篇 |
2016年 | 34篇 |
2015年 | 48篇 |
2014年 | 57篇 |
2013年 | 84篇 |
2012年 | 106篇 |
2011年 | 121篇 |
2010年 | 83篇 |
2009年 | 74篇 |
2008年 | 100篇 |
2007年 | 112篇 |
2006年 | 109篇 |
2005年 | 101篇 |
2004年 | 97篇 |
2003年 | 80篇 |
2002年 | 78篇 |
2001年 | 68篇 |
2000年 | 95篇 |
1999年 | 79篇 |
1998年 | 72篇 |
1997年 | 60篇 |
1996年 | 54篇 |
1995年 | 54篇 |
1994年 | 58篇 |
1993年 | 44篇 |
1992年 | 77篇 |
1991年 | 50篇 |
1990年 | 62篇 |
1989年 | 68篇 |
1988年 | 66篇 |
1987年 | 57篇 |
1986年 | 50篇 |
1985年 | 39篇 |
1984年 | 40篇 |
1983年 | 31篇 |
1982年 | 28篇 |
1981年 | 23篇 |
1980年 | 24篇 |
1979年 | 17篇 |
1978年 | 26篇 |
1977年 | 24篇 |
1974年 | 18篇 |
1971年 | 14篇 |
1970年 | 16篇 |
1968年 | 13篇 |
排序方式: 共有2913条查询结果,搜索用时 0 毫秒
51.
52.
Niven Mehra Karim Fizazi Johann S de Bono Philippe Barthlmy Tanya Dorff Adam Stirling Jean-Pascal Machiels Davide Bimbatti Deepak Kilari Herlinde Dumez Consuelo Buttigliero Inge M van Oort Elena Castro Hsiang-Chun Chen Nicola Di Santo Liza DeAnnuntis Cynthia G Healy Giorgio V Scagliotti 《The oncologist》2022,27(10):e783
BackgroundThe phase II TALAPRO-1 study () demonstrated durable antitumor activity in men with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). Here, we detail the safety profile of talazoparib.Patients and MethodsMen received talazoparib 1 mg/day (moderate renal impairment 0.75 mg/day) orally until radiographic progression, unacceptable toxicity, investigator decision, consent withdrawal, or death. Adverse events (AEs) were evaluated: incidence, severity, timing, duration, potential overlap of selected AEs, dose modifications/discontinuations due to AEs, and new clinically significant changes in laboratory values and vital signs.ResultsIn the safety population (N = 127; median age 69.0 years), 95.3% (121/127) experienced all-cause treatment-emergent adverse events (TEAEs). Most common were anemia (48.8% [62/127]), nausea (33.1% [42/127]), decreased appetite (28.3% [36/127]), and asthenia (23.6% [30/127]). Nonhematologic TEAEs were generally grades 1 and 2. No grade 5 TEAEs or deaths were treatment-related. Hematologic TEAEs typically occurred during the first 4-5 months of treatment. The median duration of grade 3-4 anemia, neutropenia, and thrombocytopenia was limited to 7-12 days. No grade 4 events of anemia or neutropenia occurred. Neither BRCA status nor alteration origin significantly impacted the safety profile. The median (range) treatment duration was 6.1 (0.4-24.9) months; treatment duration did not impact the incidence of anemia. Only 3 of the 15 (11.8% [15/127]) permanent treatment discontinuations were due to hematologic TEAEs (thrombocytopenia 1.6% [2/127]; leukopenia 0.8% [1/127]).ConclusionCommon TEAEs associated with talazoparib could be managed through dose modifications/supportive care. Demonstrated efficacy and a manageable safety profile support continued evaluation of talazoparib in mCRPC.ClinicalTrials.gov identifier NCT03148795 NCT03148795相似文献
53.
Sean Rayner Aiste Vitkauskaite Kevin Healy Keith Lyons Leona McSharry Dayle Leonard John P. Dunbar Michel M. Dugon 《Toxins》2022,14(9)
Venom compositions include complex mixtures of toxic proteins that evolved to immobilize/dissuade organisms by disrupting biological functions. Venom production is metabolically expensive, and parsimonious use is expected, as suggested by the venom optimisation hypothesis. The decision-making capacity to regulate venom usage has never been demonstrated for the globally invasive Noble false widow Steatoda nobilis (Thorell, 1875) (Theridiidae). Here, we investigated variations of venom quantities available in a wild population of S. nobilis and prey choice depending on venom availability. To partially determine their competitiveness, we compared their attack rate success, median effective dose (ED50) and lethal dose (LD50), with four sympatric synanthropic species: the lace webbed spider Amaurobius similis, the giant house spider Eratigena atrica, the missing sector orb-weaver Zygiella x-notata, and the cellar spider Pholcus phalangioides. We show that S. nobilis regulates its venom usage based on availability, and its venom is up to 230-fold (0.56 mg/kg) more potent than native spiders. The high potency of S. nobilis venom and its ability to optimize its usage make this species highly competitive against native European spiders sharing the same habitats. 相似文献
54.
55.
Patricia Leahy‐Warren PhD MSc BSc Hdip PHN RPHN RM RGN Mary Rose Day DN MA BSc Hdip PHN RPHN RM RGN Kari Glavin PhD M.Sc PHN RN MEANS Edith Roth Gjevjon PhD MSc RN MEANS Anne Kjersti Myhrene Steffenak PhD MSc PHN RN Live S. Nordhagen MSc PHN RN Hilde Egge MSc PHN RN Elizabeth Healy MSc PHN RGN 《Public health nursing (Boston, Mass.)》2018,35(4):307-316
56.
57.
Ms. Wendy W. Livingston MS Joseph M. Healy Jr. PhD Harmon S. Jordan ScD Cheryl K. Warner MD James L. Zazzali BA 《Journal of general internal medicine》1994,9(7):385-389
Objective: To determine the perceived needs of perimenopausal women regarding the management of menopause and the resource needs of the clinicians who treat them. Setting: A large staff and group network model health maintenance organization (HMO) in New England. Participants: A random sample of 790 perimenopausal women aged 45–60 years who were members of the HMO in 1991, and a random sample of 180 clinicians in internal medicine, family practice, and obstetrics/gynecology practicing in the HMO during 1991. Method: Mailed surveys of women and clinicians were designed to assess possible needs and attitudes that could lead to the improvement of care for menopausal women. The chi-square test was used to determine differences in perceived needs and satisfaction levels among women with differences in self-reported menopausal status. The Kruskal-Wallis one-way analysis of variance and the Mann-Whitney U test were used in the clinician survey to test for differences among specialties and between genders. Results: The key findings include that: 1) most (81%) of the women wanted to see a woman clinician, 2) many (50%) were interested in a menopause support group, 3) 30% reported that their care for menopause had been fair to poor, 4) only 55% of the primary care specialists (including internal medicine and family practice) reported high confidence in their abilities to treat menopause, compared with 68% of the obstetric/gynecology clinicians, and 5) 56% of the clinicians surveyed said that support from the HMO to their practices for the treatment of menopause was fair to poor. Conclusions: There is an opportunity for better care for perimenopausal women as reported by two sources, HMO clinicians and members. To provide this care, clinicians may need explicit guidelines as well as administrative supports such as educational materials and specialty access. Since the capability for menopausal care from clinicians in obstetrics/gynecology is perceived to be higher than that from primary care clinicians, an opportunity for cross-specialty collaboration and training may exist. 相似文献
58.
Factors that affect human hemopoiesis are produced by T-cell growth factor dependent and independent cultured T-cell leukemia-lymphoma cells 总被引:3,自引:0,他引:3
Some laboratory results and clinical situations suggest that human T cells may be important in the regulation of growth of hematopoietic cells. Since the discovery of T-cell growth factor (TCGF), systems are now available for the long-term specific in vitro propagation of mature normal or neoplastic human T cells, providing an opportunity to study the influence of T cells on hematopoiesis. Recently, 24 cell lines from patients with cutaneous T-cell lymphoma (CTCL) and T-cell acute lymphoblastic leukemia (T-ALL) were grown with TCGF and then assessed for release of humoral factors that affect hematopoiesis. Conditioned media (CM) from these cell lines were tested for erythroid burst- promoting activity (BPA) and granulocyte colony-stimulating activity (CSA). BPA was detected in CM from 3/6 cultures of T-ALL patients and 4/6 CTCL cultures. CSA was found in the CM from 6/8 cultures of T-ALL patients, 7/12 CTCL cultures, and 3/4 CTCL cell lines that become independent of exogenous TCGF for growth. The CSA from several of the neoplastic T-cell cultures stimulated high levels of eosinophil colonies, a possible source of the eosinophilia seen in these patients. The ability of continuously proliferating human T lymphocytes, which retain functional specificity and responsiveness to normal humoral regulation, to produce factors that directly or indirectly stimulate myeloid and erythroid colony formation lends further credence to the role of T lymphocytes in regulating hematopoiesis. 相似文献
59.
T Huo M Q Ye D P Healy 《Proceedings of the National Academy of Sciences of the United States of America》1991,88(8):3170-3174
Dopamine (DA) produces a natriuretic/diuretic response in the kidney by mechanisms that are still not well understood. There is some indication that DA2 receptors may be involved in mediating the effects of DA, but little is known regarding the nature of this receptor in the kidney. Autoradiographic localization of [3H]spiperone, a DA2 antagonist, indicated that high-density binding was restricted to inner medullary collecting ducts (IMCDs). [3H]Spiperone binding was saturable, high affinity (Kd, 17.2 +/- 1.65 nM), and high density (Bmax, 935 +/- 83 fmol per mg of protein). The photosensitive spiperone analogue N-(p-azido-m-[125I]iodophenethyl)spiperone labeled similar sized proteins of Mr = 120,000 in membranes prepared from the kidney inner medulla, striatum, and pituitary. However, the rank-order competition profile for the [3H]spiperone binding in the kidney inner medulla differed from the DA2 receptor in striatum and pituitary and, furthermore, RNA (Northern) blot analyses of kidney inner medullary RNA with brain DA2 receptor oligonucleotide probes were negative. Functionally, DA stimulated prostaglandin E2 production by IMCD cells, an effect that could be blocked by the DA2 antagonist domperidone. These results indicate that the kidney inner medulla expresses a functional DA receptor that may represent a newly identified DA receptor subtype (here designated DA2K). Moreover, these results suggest that the kidney inner medulla may be a significant site at which DA, either directly or indirectly, influences water and electrolyte excretion. 相似文献
60.
High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy 总被引:2,自引:1,他引:2
Brown RA; Herzig RH; Wolff SN; Frei-Lahr D; Pineiro L; Bolwell BJ; Lowder JN; Harden EA; Hande KR; Herzig GP 《Blood》1990,76(3):473-479
Seventy-five patients with resistant acute leukemia or lymphoma received high-dose cyclophosphamide and etoposide to explore the activity of this combination in resistant hematologic malignancies, and to determine the maximum doses of these drugs that can be combined without bone marrow transplantation. Etoposide was administered over 29 to 69 hours by continuous infusion corresponding to total doses of 1.8 g/m2 to 4.8 g/m2. Cyclophosphamide, 50 mg/kg/d, was administered on 3 or 4 consecutive days total 150 to 200 mg/kg ideal body weight). At all dose levels myelosuppression was severe but reversible. Mucosal toxicity was dose-limiting with the maximum tolerated dose level combining etoposide 4.2 g/m2 with cyclophosphamide 200 mg/kg. Continuous etoposide infusion produced stable plasma levels that were lower than would be achieved after administration by short intravenous infusion, and this could explain our ability to escalate etoposide above the previously reported maximum tolerated dose. There were 28 complete (35%) and 12 partial (16%) responses. Median duration of complete response (CR) was 3.5 months (range 1.1 to 20+). Seventeen of 40 patients (42%) with acute myelogenous leukemia (AML) achieved CR, including 6 of 20 (30%) with high-dose cytosine arabinoside resistance. We conclude that bone marrow transplantation is not required after maximum tolerated doses of etoposide and cyclophosphamide. This regimen is active in resistant hematologic neoplasms, and the occurrence of CR in patients with high-dose cytosine arabinoside-resistant AML indicates a lack of complete cross-resistance between these regimens. 相似文献